UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     
Date of Report (Date of Earliest Event Reported):   March 6, 2015

Biolase, Inc.
__________________________________________
(Exact name of registrant as specified in its charter)

     
Delaware 000-19627 87-0442441
_____________________
(State or other jurisdiction 		_____________
(Commission 		______________
(I.R.S. Employer
of incorporation) File Number) Identification No.)
      
4 Cromwell, Irvine, California   92618
_________________________________
(Address of principal executive offices) 		  ___________
(Zip Code)
     
Registrant’s telephone number, including area code:   949-361-1200

Not Applicable
______________________________________________
Former name or former address, if changed since last report

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[  ]  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[  ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[  ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[  ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Top of the Form

Item 8.01 Other Events.

On March 6, 2015, Biolase, Inc. (the "Company") issued a press release announcing the date of the Company’s 2015 Annual Meeting of Stockholders and the record date for such meeting, a copy of which is attached hereto as Exhibit 99.1 and incorporated herein by reference.

The deadline for notice of stockholder proposals and nominations under the Company’s amended and restated bylaws is March 16, 2015, and the deadline for submitting stockholder proposals for inclusion in the Company’s proxy statement and form of proxy under Rule 14a-8 under the Securities Exchange Act of 1934 is March 26, 2015.





Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

99.1 Press Release of Biolase, Inc. issued on March 6, 2015





Top of the Form

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

         
    Biolase, Inc.
          
March 6, 2015   By:   Jeffrey M. Nugent
       
        Name: Jeffrey M. Nugent
        Title: President and Chief Executive Officer

Top of the Form

Exhibit Index


     
Exhibit No.   Description
 
99.1
  Press Release of Biolase, Inc., dated March 6, 2015.
EX-99.1

BIOLASE Announces Annual Meeting Date and Record Date

IRVINE, Calif.— March 6, 2015— BIOLASE, Inc. (NASDAQ:BIOL), the global leader in dental lasers, is pleased to announce that its 2015 Annual Meeting of Stockholders will be held on April 27, 2015, at 11:00 a.m. Pacific Time at the Company’s corporate headquarters, located at 4 Cromwell, Irvine, California 92618. The Board of Directors has established April 1, 2015 as the record date for determining the stockholders entitled to vote at the 2015 Annual Meeting of Stockholders.

The deadline for notice of stockholder proposals and nominations under the Company’s amended and restated bylaws is March 16, 2015, and the deadline for submitting stockholder proposals for inclusion in the Company’s proxy statement and form of proxy under Rule 14a-8 under the Securities Exchange Act of 1934 is March 26, 2015.  

* * * * *

About BIOLASE, Inc.

BIOLASE, Inc. is a medical device company that develops, manufactures, and markets innovative lasers in dentistry and medicine and also markets and distributes high-end 2D and 3D digital imaging equipment, CAD/CAM intraoral scanners, and in-office milling machines and 3D printers. BIOLASE’s products are focused on technologies that advance the practice of dentistry and medicine and offer benefits and value to healthcare professionals and their patients. The Company’s proprietary laser products incorporate approximately 250 patented and 100 patent-pending technologies designed to provide biologically clinically superior performance with less pain and faster recovery times. Its innovative products provide cutting-edge technology at competitive prices to deliver the best results for dentists and patients. BIOLASE’s principal products are revolutionary dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications, and a full line of dental imaging equipment. BIOLASE has sold approximately 27,600 laser systems. Laser products under development address the Company’s core dental market and other adjacent medical and consumer markets.

For updates and information on WaterLase and laser dentistry, find BIOLASE online at www.biolase.com, Facebook at www.facebook.com/biolase, Twitter at www.twitter.com/biolaseinc, Pinterest at www.pinterest.com/biolase, LinkedIn at www.linkedin.com/company/biolase, Google+ at www.google.com/+BIOLASEIrvine, Instagram at www.instagram.com/biolaseinc, and YouTube at www.youtube.com/biolasevideos.

BIOLASE® and WaterLase® are registered trademarks of BIOLASE, Inc.

Source: BIOLASE, Inc.

CONTACT:

Daniel Goldstein / Steven Goldberg
Sard Verbinnen & Co
310-201-2040

# # #